Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-B7-H3 antibody drug conjugate, vobra duo + [1] |
Target |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 3 | US | 11 Jul 2022 | |
Melanoma | Phase 3 | US | 11 Jul 2022 | |
Non-Small Cell Lung Cancer | Phase 3 | US | 11 Jul 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 21 Nov 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | PL | 21 Nov 2018 | |
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 21 Nov 2018 | |
Triple Negative Breast Cancer | Phase 2 | US | 21 Nov 2018 | |
Triple Negative Breast Cancer | Phase 2 | PL | 21 Nov 2018 | |
Neoplasms | Phase 2 | - | - | |
Advanced Malignant Solid Neoplasm | Preclinical | ES | 21 Nov 2018 |
NCT03729596 (ASCO2021) Manual | Phase 1 | 29 | MGC018 | (pvurtltjsh) = vyrohwntvh tlgahokjef (bjljtjpitd ) View more | Positive | 28 May 2021 | |
Phase 2 | 176 | Vobramitamab duocarmazine (vobra duo) 2.0 mg/kg q4W | (qngrxrydsx) = lslvpmxhdd cwbzoyygpu (fwkfgtcllw ) View more | Positive | 09 May 2024 | ||
Vobramitamab duocarmazine (vobra duo) 2.7 mg/kg q4W | (qngrxrydsx) = ifukmrawxg cwbzoyygpu (fwkfgtcllw ) View more | ||||||
Phase 1 | 49 | lhdxteurrk(ehuibjmypm) = ijswryfmvs xazbcgflzf (cshgbghglg ) | - | 16 Sep 2021 | |||
Phase 2 | 177 | Vobra duo 2.0 mg/kg | (xuqmfovnxu) = rhoexuyiti ajuiiuzhho (xogcivckfv ) View more | Positive | 03 Apr 2024 | ||
Vobra duo 2.7 mg/kg | (xuqmfovnxu) = bwsqihhlpq ajuiiuzhho (xogcivckfv ) View more |